EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data

Karin Zebenholzer iD, Andreas Gleiss, Berthold Reichardt, Walter Gall, Christian Wöber

European Journal of Neurology · 2025

DOI: 10.1111/ene.70440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Karin Zebenholzer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide, Antibodies, Monoclonal, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Insurance data allow insights into dispensations of medications. This retrospective study over 49 months examined dispensations of monoclonal antibodies against calcitonin gene‐related peptide (CGRP‐mAbs).

Methods

Using nationwide insurance data, we examined dispensations of erenumab, fremanezumab, or galcanezumab from September 1, 2018 to September 30, 2022. We examined the duration of treatment and breaks (Kaplan–Meier curves, medians, quartiles), persistence (proportion of days covered), and switches, acute medications, and other preventatives.

Results

Of 8.8 million persons, 8934 were at least once dispensed a CGRP‐mAb (83.5% women, median age 45 years). Median individual follow‐up time was 710 days, median duration of treatment with any CGRP‐mAb was 297 days, 42.9% had CGRP‐mAbs for at least 1 year. Median duration of treatment with the first‐ever CGRP‐mAb was 327 days; 63.4% experienced a therapy break. Within 1 year after stopping, 53.5% resumed the same CGRP‐mAb, 16.9% another CGRP‐mAb, 29.6% did not resume any CGRP‐mAb; 13.7% started a second CGRP‐mAb and 1.7% a third. 22% definitively stopped therapy within their follow‐up. Dispensation of triptans decreased during and after therapy with CGRP‐mAbs; dispensation of other acute prescription medications was low without change. 11.4% had other preventatives before and 2.4% during CGRP‐mAb therapy. The proportion of days covered was 96%.

Conclusions

In this nationwide study persistence with CGRP‐mAbs was excellent; dispensations of triptans and other preventatives decreased during CGRP‐mAb therapy. Therapy breaks were common, but the majority resumed CGRP‐mAbs, which indicates the need for long‐term prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCalcitonin Gene-Related PeptideAntibodies, MonoclonalCalcitonin Gene-Related Peptide Receptor AntagonistsDrug PrescriptionsHumansFemaleRetrospective StudiesMiddle AgedMaleAdultAustriaLongitudinal StudiesAntibodies, Monoclonal, HumanizedAgedYoung Adult

Stichwörter der Autor:innen

CGRP‐mAbsmigraine preventativespersistencepharmacoepidemiologic studytreatment break

Substanzen

Calcitonin Gene-Related PeptideerenumabAntibodies, MonoclonalfremanezumabAntibodies, Monoclonal, HumanizedgalcanezumabCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Department of Neurology, Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, Vienna, Austria.
  • Center for Medical Data Science, Institute of Clinical Biometrics, Medical University of Vienna, Vienna, Austria.
  • Austrian Social Health Insurance Fund, Vienna, Austria.
  • Center for Medical Data Science, Institute of Medical Information Management, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Karin Zebenholzer

Zitieren

APA

Zebenholzer, K., Gleiss, A., Reichardt, B., Gall, W., & Wöber, C. (2025). Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data. European Journal of Neurology. https://doi.org/10.1111/ene.70440

Vancouver

Zebenholzer K, Gleiss A, Reichardt B, Gall W, Wöber C. Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data. European Journal of Neurology. 2025. doi:10.1111/ene.70440

BibTeX
@article{Zebenholzer2025,
  author = {Zebenholzer, Karin and Gleiss, Andreas and Reichardt, Berthold and Gall, Walter and Wöber, Christian},
  title = {Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70440}
}
Kostenlos starten →